AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

Recruitingn/aAges 18 Years - anyAllAstraZeneca
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This multicenter pilot study will enroll adult participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure (HF) controls with documentation within the past 2 years that either excludes ATTR-CM or indicates a low probability of ATTR-CM. Ocular imaging and other study data will be collected to assess the feasibility of developing and preliminarily evaluating a machine learning model to discriminate ATTR-CM cases from HF controls without ATTR-CM.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * 1\. Participant must be 18 years and older at the time of signing the informed consent form. * 2\. Participants with either of the following: * \- Positive ATTR-CM cases: Participants with a clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) with amyloid deposits in cardiac or non-cardiac tissue confirmed by Congo Red (or equivalent) staining, or DPD-Tc, PYP-Tc, or HMDP-Tc scintigraphy with Grade 2 or 3 cardiac uptake in the absence of abnormal light chains ratio. * \- Control population: Participants with a clinical diagnosis of guideline-directed medical therapy-directed heart failure (HF) and either: * a) Subgroup A: Definitively excluded ATTR-CM amyloidosis: negative cardiac or non-cardiac tissue biopsy for amyloid, or negative technetium scintigraphy within the past 2 years. * b) Subgroup B: Low probability of ATTR-CM amyloidosis, not definitively excluded: absence of amyloid-suggestive features on echocardiography (ECHO), electrocardiography (ECG), or cardiac magnetic resonance imaging (MRI) within the past 2 years, with documented clinical assessment indicating HF etiology unlikely attributable to amyloidosis; no amyloid-specific testing (technetium scintigraphy or biopsy) performed. * 3\. Participant or legally authorized representative (LAR) must sign the informed consent form. Exclusion Criteria: * 1\. Any known eye condition that may preclude clear imaging of the retina. * 2\. Any known history of amyloid light-chain (AL) amyloidosis. * 3\. Any ocular surgery that, in the opinion of the investigator, makes participation in the study undesirable. * 4\. Any medical condition that, in the opinion of the investigator, makes participation in the study undesirable, for example, if the participant is critically unwell or requires ongoing emergency treatment. * 5\. Involvement in the planning and/or conduct of the study. * 6\. In the opinion of the investigator, the participant is unlikely to comply with study procedures, restrictions, and requirements. * 7\. Previous enrollment in the present study.
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

20 sites
Research Site
Palo Alto, United States
Research Site
Jacksonville, United States
Research Site
Chicago, United States
Research Site
Boston, United States
Research Site
Portland, United States
Research Site
Germantown, United States
Research Site
Berlin, Germany
Research Site
Essen, Germany

โ€ฆand 12 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy